Vaxcyte (PCVX) Resumen de Acciones
Vaxcyte, Inc., una empresa de innovación en vacunas en fase clínica, desarrolla vacunas conjugadas y nuevas vacunas proteicas para prevenir o tratar enfermedades infecciosas bacterianas. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
PCVX Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeCompetidores de Vaxcyte, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$51.48 |
| Máximo en las últimas 52 semanas | US$65.00 |
| Mínimo de 52 semanas | US$28.64 |
| Beta | 1.3 |
| Cambio en 1 mes | -15.18% |
| Variación en 3 meses | -8.32% |
| Cambio de 1 año | 63.69% |
| Variación en 3 años | 2.86% |
| Variación en 5 años | 169.67% |
| Variación desde la OPV | 96.86% |
Noticias y actualizaciones recientes
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market
Summary Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets broader serotype coverage than competitors and is in pivotal Phase 3 adult and Phase 2 infant trials. PCVX boasts strong financials, with over $2.4B in cash and a completed manufacturing facility, enabling concurrent late-stage development and commercial preparation. Key catalysts include the OPUS-1 Phase 3 readout in Q4 2026, with further adult and infant data in 2027, positioning PCVX as a next-generation vaccine leader. Read the full article on Seeking Alpha
Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity
Catalysts About Vaxcyte Vaxcyte is a vaccine company focused on developing broader-coverage pneumococcal and Group A Strep vaccines for adult and pediatric use. What are the underlying business or industry changes driving this perspective?Recent updates
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market
Summary Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets broader serotype coverage than competitors and is in pivotal Phase 3 adult and Phase 2 infant trials. PCVX boasts strong financials, with over $2.4B in cash and a completed manufacturing facility, enabling concurrent late-stage development and commercial preparation. Key catalysts include the OPUS-1 Phase 3 readout in Q4 2026, with further adult and infant data in 2027, positioning PCVX as a next-generation vaccine leader. Read the full article on Seeking AlphaFuture Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity
Catalysts About Vaxcyte Vaxcyte is a vaccine company focused on developing broader-coverage pneumococcal and Group A Strep vaccines for adult and pediatric use. What are the underlying business or industry changes driving this perspective?
Late Stage Vaccine Programs And New Manufacturing Capacity Will Underpin Long Term Upside
Catalysts About Vaxcyte Vaxcyte is a vaccine company focused on pneumococcal conjugate vaccines and a Group A Strep program, using a carrier sparing platform to target broad disease coverage. What are the underlying business or industry changes driving this perspective?
Late Stage Vaccine Trials And Manufacturing Buildout Will Shape Balanced Long Term Outlook
Catalysts About Vaxcyte Vaxcyte is a vaccine company developing pneumococcal conjugate vaccines and a Group A Strep candidate using a carrier sparing platform and large scale manufacturing infrastructure. What are the underlying business or industry changes driving this perspective?We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
Summary Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035. VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it. PCVX is attempting to expand its program in the prevention of IPD with candidates VAX-31 and VAX-XL; The goal is broaden the disease that can be targeted. Read the full article on Seeking AlphaVaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Summary Vaxcyte's stock surged 68% since August 2023, driven by progress with its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, covering 95.6% of serotypes, has been selected over VAX-24 for Phase 3 trials, with topline data expected in 2026. Vaxcyte's robust financial position, with over $3 billion in cash and investments, supports its strategic flexibility and extended timelines. The expanded market guidelines and projected PCV market growth to $12 billion bolster Vaxcyte's potential, with VAX-31's NPV estimated at $13.5 billion upon approval. Despite recent weakness, maintaining a buy rating based on upcoming Phase 3 catalyst and strong cash position, though high valuation presents risks. Read the full article on Seeking AlphaVaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Summary Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market. Investors should consider potential risks and wait for market stabilization post-fundraising, but the long-term upside remains compelling with possible +75% upside in play, in my view. There are some risks to consider - length of time to potential approval the most prominent - but it's rare to see such a compelling data set when market incumbents are so established. Read the full article on Seeking AlphaRentabilidad de los accionistas
| PCVX | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -10.1% | 1.2% | 2.1% |
| 1Y | 63.7% | 41.9% | 30.6% |
Rentabilidad vs. Industria: PCVX superó a la industria US Biotechs, que obtuvo un rendimiento del 41.9% el año pasado.
Rentabilidad vs. Mercado: PCVX superó al mercado US, que obtuvo un rendimiento del 30.6% el año pasado.
Volatilidad de los precios
| PCVX volatility | |
|---|---|
| PCVX Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: PCVX no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de PCVX (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2013 | 507 | Grant Pickering | vaxcyte.com |
Vaxcyte, Inc. es una empresa de innovación en vacunas en fase clínica que desarrolla vacunas conjugadas y nuevas vacunas proteicas para prevenir o tratar enfermedades infecciosas bacterianas. Su principal vacuna candidata es VAX-24, una vacuna antineumocócica conjugada (VNC) en fase de investigación, 24-valente y sin portador, para la prevención de la enfermedad neumocócica invasiva (ENI) en lactantes. La empresa también desarrolla VAX-31, una vacuna antineumocócica conjugada en fase de investigación, 31-valente y sin portador, para la prevención de la enfermedad neumocócica invasiva en adultos y niños; VAX-A1, una nueva vacuna conjugada candidata para prevenir la enfermedad causada por el estreptococo del grupo A; VAX-PG, una nueva vacuna proteica contra el patógeno clave responsable de la periodontitis; VAX-GI, una nueva vacuna preclínica para el tratamiento de la disentería y la shigelosis, causadas por la bacteria Shigella; y VAX-XL, una vacuna antineumocócica conjugada de tercera generación.
Resumen de fundamentos de Vaxcyte, Inc.
| Estadísticas fundamentales de PCVX | |
|---|---|
| Capitalización bursátil | US$8.24b |
| Beneficios(TTM) | -US$946.53m |
| Ingresos (TTM) | n/a |
¿Está PCVX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de PCVX | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$946.53m |
| Beneficios | -US$946.53m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -6.56 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado PCVX a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/07 20:15 |
| Precio de las acciones al final del día | 2026/05/07 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Vaxcyte, Inc. está cubierta por 15 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Thomas Shrader | BTIG |
| Carter Gould | Cantor Fitzgerald & Co. |